Can Erdafitinib be purchased in domestic pharmacies?

Erdafitinib (Erdafitinib) is an oral targeted drug that has attracted much attention in recent years. It is mainly a fibroblast growth factor receptor (FGFR) inhibitor. Its research and development background is closely related to precision medicine, and it has been approved overseas for the treatment of patients with locally advanced or metastatic bladder cancer carrying FGFR gene abnormalities. Different from traditional chemotherapy, erdafitinib exerts its anti-tumor effect by specifically inhibiting the FGFR signaling pathway. Such genetic abnormalities are often important driving factors for the unlimited proliferation of tumor cells. Therefore, the indications for erdafitinib are clear, that is, patients who need genetic testing to confirm the presence of FGFR2 or FGFR3 gene mutations or fusions can benefit from it.

In the domestic market, erdafitinib has been approved for marketing and is available in various specifications, including5mg 28 tablets, 3mg 56 tablets and 4mg*28 tablets. These dosages are designed to provide patients with flexible choices for individualized treatment. However, because it is a drug that has recently entered the Chinese market and has not yet been included in the national medical insurance catalog, the purchase cost is relatively high. In addition, it has not been on the market for a long time and the distribution channels are still being gradually improved, making it difficult for most ordinary retail pharmacies to purchase the drug directly. Usually, patients need to apply through professional hospital pharmacies or formal imported drug channels. Some patients will also choose to purchase drugs overseas. However, in this way, attention must be paid to the legal compliance of the channel to ensure drug quality and efficacy.

Compared with other traditional treatments, the application of erdafitinib is groundbreaking. For some patients with FGFR gene-positive bladder cancer, it provides a more targeted treatment, which can help delay the progression of the disease and improve the patient's quality of life. In the future, as more research data accumulates, the indications of erdafitinib are expected to be further expanded, and clinical exploration in some cholangiocarcinomas and other solid tumors is currently underway.

Reference materials：https://www.balversa.com/